Intravesical suramin in the prevention of transitional cell carcinoma.
OBJECTIVE
To examine the effects of intravesical suramin on N-methyl-N-nitrosurea (MNU)-induced bladder tumors in Fischer 344 rats.


METHODS
Multiple cohorts of female rats received four biweekly intravesical instillations of MNU. A control group received no other treatment, the experimental group received 25 mg/kg intravesical suramin twice a week beginning at week 6.


RESULTS
After 18 weeks from the first instillation of MNU, 60% to 65% of control animals developed papillary transitional cell carcinoma, compared with only 0% to 10% of the suramin-treated animals (P = 0.01 to P = 0.0007). There was no local or systemic toxicity observed.


CONCLUSIONS
Intravesical suramin is an effective chemopreventative therapy for transitional cell carcinoma in vivo with minimal toxicity.
Graham
S D
SD
Department of Surgery, Emory University School of Medicine, Atlanta, Georgia.
Napalkov
P
P
Oladele
A
A
Keane
T E
TE
Petros
J A
JA
Clarke
H S
HS
Kassabian
V S
VS
Dillehay
D L
DL
D000283:Administration, Intravesical; D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000517:prevention & control*; D005260:Female; D008770:Methylnitrosourea; D051381:Rats; D011916:Rats, Inbred F344; D013498:Suramin / Q000008:administration & dosage* / Q000097:blood / Q000633:toxicity; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000517:prevention & control*
D013498:Suramin; D008770:Methylnitrosourea